US FDA allows use of Bristol's cell therapy for rare blood cancer-February 2024-www.financetom.com

US FDA allows use of Bristol's cell therapy for rare blood cancer

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA allows use of Bristol's cell therapy for rare blood cancer

May 30, 2024 9:06 AM

May 30 (Reuters) - The U.S. Food and Drug Administration

has allowed expanded use of Bristol Myers Squibb's ( BMY ) cell

therapy, Breyanzi, for an aggressive and rare type of blood

cancer that affects the body's disease fighting cells, the

company said on Thursday.

Previous page： Russian court imposes $38,000 fine on Alphabet's Google for non-compliance Next page： HCW Biologics, WY Biotech Sign License Deal for Immunotherapeutic Product Candidate

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Russian court imposes $38,000 fine on Alphabet's Google for non-compliance

Nov 18, 2024

MOSCOW, Nov 18 (Reuters) - A Russian district court fined Alphabet's Google 3.8 million roubles ($38,057) on Monday for failing to remove banned content. Russia has for several years ordered foreign technology platforms to remove content it deems illegal, issuing small, but persistent fines when it sees failures to comply. ($1 = 99.8500 roubles) ...

HCW Biologics, WY Biotech Sign License Deal for Immunotherapeutic Product Candidate

Nov 18, 2024

08:14 AM EST, 11/18/2024 (MT Newswires) -- HCW Biologics ( HCWB ) and WY Biotech said Monday they struck a license deal to develop and commercialize one of the former's immunotherapeutic product candidates. Under the terms, HCW Biologics ( HCWB ) will receive a $7 million upfront payment from WY Biotech, while the latter will cover all expenses regarding research...

Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA

Nov 18, 2024

08:01 AM EST, 11/18/2024 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Monday that the US Food and Drug Administration has accepted its resubmitted new drug application for its topical ocular reproxalab, a treatment for dry eye disease. The company said the FDA has assigned a Prescription Drug User Fee Act date of April 2. Aldeyra has also expanded...

Manulife CEO Roy Gori to retire in May 2025

Nov 18, 2024

Nov 18 (Reuters) - Canadian insurer Manulife Financial ( MFC ) said on Monday Chief Executive Officer Roy Gori will retire, effective May 8, 2025. (Reporting by Arasu Kannagi Basil in Bengaluru) ...